| Zydus |
12 |
$102.1B |
Entresto, Farxiga, Opsumit, Xtandi, Lynparza, Keytruda, Otezla, Jardiance, Vraylar, Ozempic, Imbruvica, Erleada |
| Cipla |
12 |
$92.7B |
Xarelto, Farxiga, Pomalyst, Lynparza, Keytruda, Otezla, Jardiance, Vyndaqel, Descovy, Cabometyx, Calquence, Biktarvy |
| Sandoz |
12 |
$80.0B |
Stelara, Prolia, Xgeva, Farxiga, Pomalyst, Januvia, Xtandi, Lynparza, Keytruda, Otezla, Enbrel, Rinvoq |
| Dr. Reddy's |
11 |
$100.1B |
Entresto, Prolia, Xgeva, Xarelto, Pomalyst, Keytruda, Jakafi, Darzalex, Cosentyx, Ozempic, Venclexta |
| Alvotech |
11 |
$77.5B |
Stelara, Prolia, Xgeva, Xolair, Simponi, Keytruda, Taltz, Tremfya, Kesimpta, Imfinzi, Entyvio |
| Teva |
11 |
$47.8B |
Stelara, Prolia, Xgeva, Farxiga, Pomalyst, Januvia, Simponi, Opsumit, Ocrevus, Cabometyx, Entyvio |
| MSN |
10 |
$41.0B |
Entresto, Xarelto, Farxiga, Pomalyst, Opsumit, Otezla, Jakafi, Cabometyx, Calquence, Erleada |
| Celltrion |
9 |
$79.5B |
Stelara, Prolia, Xgeva, Xolair, Keytruda, Darzalex, Cosentyx, Taltz, Tremfya |
| Samsung Bioepis |
9 |
$79.0B |
Stelara, Prolia, Xgeva, Keytruda, Enbrel, Taltz, Dupixent, Tremfya, Entyvio |
| Apotex |
9 |
$50.4B |
Xarelto, Pomalyst, Januvia, Opsumit, Xtandi, Jakafi, Vyndaqel, Descovy, Ozempic |
| Lupin |
8 |
$62.4B |
Entresto, Xarelto, Farxiga, Xtandi, Eliquis, Descovy, Erleada, Biktarvy |
| Biocon |
8 |
$39.6B |
Entresto, Stelara, Prolia, Xgeva, Xarelto, Farxiga, Perjeta, Cabometyx |
| Sun Pharma |
7 |
$43.2B |
Pomalyst, Opsumit, Jakafi, Vraylar, Invega Sustenna, Ozempic, Rinvoq |
| Intas (Accord) |
7 |
$41.8B |
Stelara, Prolia, Xgeva, Simponi, Eliquis, Invega Sustenna, Rinvoq |
| Alembic |
7 |
$32.9B |
Entresto, Xarelto, Farxiga, Opsumit, Lynparza, Jakafi, Venclexta |
| Aurobindo |
6 |
$35.6B |
Entresto, Xarelto, Farxiga, Opsumit, Vraylar, Rinvoq |
| Hetero |
6 |
$29.0B |
Entresto, Pomalyst, Descovy, Imbruvica, Erleada, Rinvoq |
| Henlius |
5 |
$56.1B |
Prolia, Xgeva, Perjeta, Keytruda, Darzalex |
| Viatris (Mylan) |
5 |
$50.8B |
Pomalyst, Opsumit, Eliquis, Ozempic, Wegovy |
| Alkem |
5 |
$26.7B |
Entresto, Xarelto, Farxiga, Otezla, Jakafi |
| Hikma |
5 |
$22.0B |
Stelara, Prolia, Xgeva, Jakafi, Vyndaqel |
| Amgen |
4 |
$56.3B |
Stelara, Keytruda, Opdivo, Ocrevus |
| Macleods |
4 |
$24.1B |
Entresto, Xarelto, Farxiga, Descovy |
| Fresenius Kabi |
4 |
$18.6B |
Stelara, Prolia, Xgeva, Entyvio |
| Bio-Thera |
4 |
$18.1B |
Stelara, Simponi, Cosentyx, Nucala |
| Micro Labs |
3 |
$28.1B |
Xarelto, Farxiga, Eliquis |
| Laurus Labs |
3 |
$24.3B |
Entresto, Opsumit, Biktarvy |
| Polpharma |
3 |
$19.6B |
Ocrevus, Tremfya, Entyvio |
| Torrent |
3 |
$12.3B |
Entresto, Opsumit, Otezla |
| Natco |
3 |
$10.0B |
Lynparza, Descovy, Imbruvica |
| Amneal |
3 |
$8.8B |
Prolia, Xgeva, Opsumit |
| Qilu |
2 |
$35.5B |
Keytruda, Invega Sustenna |
| Alvogen |
2 |
$23.3B |
Ozempic, Imbruvica |
| Regcon |
2 |
$19.7B |
Xarelto, Eliquis |
| Ascent |
2 |
$11.3B |
Xarelto, Xtandi |
| Breckenridge |
2 |
$8.0B |
Xarelto, Pomalyst |
| Mankind |
2 |
$7.6B |
Xarelto, Otezla |
| Eugia |
2 |
$5.8B |
Pomalyst, Jakafi |
| BioNTech |
1 |
$31.7B |
Keytruda |
| Formycon |
1 |
$31.7B |
Keytruda |
| mAbxience |
1 |
$31.7B |
Keytruda |
| Rio Biopharmaceuticals |
1 |
$19.3B |
Ozempic |
| Chong Kun Dang |
1 |
$17.8B |
Dupixent |
| CSPC |
1 |
$17.8B |
Dupixent |
| CinnaGen |
1 |
$8.4B |
Ocrevus |
| Aizant |
1 |
$8.4B |
Farxiga |
| Ajanta |
1 |
$8.4B |
Farxiga |
| Inventia |
1 |
$8.4B |
Farxiga |
| Crystal Pharmaceutical |
1 |
$7.7B |
Entresto |
| Novugen |
1 |
$7.7B |
Entresto |
| Somerset Therapeutics |
1 |
$7.7B |
Entresto |
| Umedica |
1 |
$7.7B |
Entresto |
| Dexcel |
1 |
$6.4B |
Vyndaqel |
| Actavis |
1 |
$6.0B |
Xtandi |
| Kashiv |
1 |
$5.4B |
Xolair |
| Aiping |
1 |
$5.3B |
Xarelto |
| Epic Pharma |
1 |
$5.3B |
Xarelto |
| ScieGen |
1 |
$5.3B |
Xarelto |
| Sunshine Lake |
1 |
$5.3B |
Xarelto |
| Taro |
1 |
$5.3B |
Xarelto |
| Boan Biotech |
1 |
$4.3B |
Trulicity |
| Transpire |
1 |
$3.9B |
Trelegy |
| Tolmar |
1 |
$3.8B |
Invega Sustenna |
| Organon |
1 |
$3.6B |
Perjeta |
| Granules |
1 |
$3.1B |
Jakafi |
| Lepu |
1 |
$2.3B |
Opsumit |
| Annora |
1 |
$2.3B |
Otezla |
| Shilpa |
1 |
$2.3B |
Otezla |
| Azurity |
1 |
$2.1B |
Cabometyx |
| Handa |
1 |
$2.1B |
Cabometyx |